Negrar
Negrar
Negrar, Italy20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care | Craniocerebral Trauma, Injuries, Acute Brain, brain disorder, brain injury, central nervous system disorder, injury, nervous system disorder, nervous system injury | Recruiting | Not stated | 2026-10-09 | NCT04905264 | |
| A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07483099 | |
| A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | Crohn disease, Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 2 | 2026-10-08 | NCT07483073 | |
| A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 | 2026-10-08 | NCT06226883 | |
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 2 | 2026-10-06 | NCT07012395 | |
| A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 2 | 2026-09-29 | NCT07845487 | |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Not yet recruiting | Phase 3 | 2026-09-29 | NCT07474649 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242484 | |
| A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT04033445 | |
| Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT05113251 | |
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma | Recruiting | Phase 2 | 2026-07-30 | NCT06486883 | |
| Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 | 2026-04-27 | NCT06456593 | |
| Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 | 2026-04-09 | NCT06290934 | |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, brain cancer, brain disorder, breast cancer, breast disorder, breast neoplasm, central nervous system cancer, central nervous system disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal cancer, esophageal disorder, female reproductive organ cancer, female reproductive system disorder, female reproductive system neoplasm, head and neck cancer, head and neck neoplasm, injury, intestinal disorder, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, neoplasm of esophagus, nervous system disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, prostate neoplasm, radiation injury, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not stated | 2026-03-05 | NCT04075305 | |
| Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | Non-small-cell Lung Cancer Patients | Active, not recruiting | Phase 2 | 2026-02-09 | NCT03896074 | |
| National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active, not recruiting | Not stated | 2026-01-30 | NCT05918666 | |
| Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Not stated | 2025-12-24 | NCT05817942 | |
| OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT) | Digestive System Diseases, Digestive System Neoplasms, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, non-small cell lung carcinoma, prostate cancer, prostate disorder, rectal disorder, skin disorder | Recruiting | Not applicable | 2025-08-01 | NCT06462963 | |
| E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | cancer, neoplasm | Recruiting | Not stated | 2025-03-21 | NCT03818503 | |
| Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | invasive breast carcinoma | Active, not recruiting | Phase 3 | 2024-03-06 | NCT03595592 |